Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Jackson

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2006
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disabilityMahmoud M Iravani, Kayhan Tayarani-Binazir, Wing B Chu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 29, 2010
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosetsKayhan A Tayarani-Binazir, Michael J Jackson, Sarah Rose, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
Journal of Parkinson'S Disease|March 1, 2024
Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced DyskinesiaClare J Finlay, Michael J Jackson, Ria Fisher, et al.
Experimental Neurology|December 31, 2002
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)Eleni C Maratos, Michael J Jackson, Ronald K B Pearce, et al.
Behavioural Pharmacology|January 13, 2012
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned ratKayhan A Tayarani-Binazir, Michael J Jackson, Isobel Strang, et al.
Neurobiology of Disease|August 18, 2010
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesiaBai-Yun Zeng, Mahmoud M Iravani, Michael J Jackson, et al.
European Journal of Pharmacology|March 23, 2010
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmosetKayhan A Tayarani-Binazir, Michael J Jackson, Ria Fisher, et al.
European Journal of Pharmacology|August 24, 2006
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosetsSarah Rose, Michael J Jackson, Lance A Smith, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2006
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disabilityMahmoud M Iravani, Kayhan Tayarani-Binazir, Wing B Chu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 29, 2010
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosetsKayhan A Tayarani-Binazir, Michael J Jackson, Sarah Rose, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
Journal of Parkinson'S Disease|March 1, 2024
Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced DyskinesiaClare J Finlay, Michael J Jackson, Ria Fisher, et al.
Experimental Neurology|December 31, 2002
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)Eleni C Maratos, Michael J Jackson, Ronald K B Pearce, et al.
Behavioural Pharmacology|January 13, 2012
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned ratKayhan A Tayarani-Binazir, Michael J Jackson, Isobel Strang, et al.
Neurobiology of Disease|August 18, 2010
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesiaBai-Yun Zeng, Mahmoud M Iravani, Michael J Jackson, et al.
European Journal of Pharmacology|March 23, 2010
The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmosetKayhan A Tayarani-Binazir, Michael J Jackson, Ria Fisher, et al.
European Journal of Pharmacology|August 24, 2006
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosetsSarah Rose, Michael J Jackson, Lance A Smith, et al.
Pageof 4